NTLA

Intellia Therapeutics, Inc. · Healthcare · Market cap $1.6B

Insiders sold $507K net in the last 90 days ·3 sellers, 0 buyers· 3 of 5 sales under Rule 10b5-1 plans· latest Form 4 filed Aug 24, 2026

Insider Buying

$1.4M

reported purchases (SEC code P)

Insider Selling

$2.2M

reported sales (SEC code S)

Unique Insiders

8

in the rolling window

Latest filing

Aug 24, 2026

LEONARD JOHN M

Intellia Therapeutics, Inc. (NTLA) has 29 SEC Form 4 filings (36 transaction rows) in the rolling window, disclosed by 8 distinct insiders. Most recent filing: Aug 24, 2026.

Inside the rolling window, 8 insiders at Intellia Therapeutics, Inc. reported 1 open-market purchase totaling $1.4M and 17 open-market sales totaling $2.2M. The most active filer is President and CEO LEONARD JOHN M with 4 filings. Insiders have net sold $532K over the trailing 6 months. The most recent open-market filing is a sale of 19,890 shares by President and CEO LEONARD JOHN M, dated Aug 20, 2026, worth $251K.

  • Industry:Biotechnology
  • CEO:John Leonard
  • Employees:377
  • HQ:Cambridge, MA, US
  • IPO:2016-05-06
Source
LEONARD JOHN MFirst in 8 months
Sale$251KAug 24SEC ↗
LEONARD JOHN MFirst in 8 months
Sale$36KAug 24SEC ↗
Sale$91KJul 24SEC ↗
Dulac Edward J IIIFirst in 6 months
Sale$84KJul 6SEC ↗
Dube Michael PFirst in 6 months
Sale$44KJul 6SEC ↗
Sale$8KMar 3SEC ↗
Sale$17KMar 3SEC ↗
Cohen Fred EFirst filing
Purchase$1.4MJan 7SEC ↗
Clark ElianaFirst filing
Sale$88KJan 7SEC ↗
BASTA JAMESFirst filing
Sale$96KJan 7SEC ↗
Dulac Edward J IIIFirst filing
Sale$59KJan 7SEC ↗
Dube Michael PFirst in 3 months
Sale$28KJan 7SEC ↗
Lebwohl DavidFirst filing
Sale$110KJan 7SEC ↗
Schultes Birgit CFirst in 3 months
Sale$78KJan 7SEC ↗
Sale$314KJan 7SEC ↗
LEONARD JOHN MFirst filing
Sale$836KDec 12SEC ↗
Schultes Birgit CFirst filing
Sale$539Oct 3SEC ↗
Dube Michael PFirst filing
Sale$33KOct 3SEC ↗
Showing 1–18 of 18
1 / 1

Congress trading NTLA 15 all-time

  • DSen. Thomas Richard CarperOther$1,001 - $15,0002023-08-25
  • DSen. Thomas Richard CarperPurchase$1,001 - $15,0002023-05-22
  • DRep. Donald Sternoff BeyerOther$15,001 - $50,0002022-02-28
  • DRep. Donald Sternoff BeyerOther$1,001 - $15,0002021-10-29
  • DRep. Donald Sternoff BeyerOther$1,001 - $15,0002021-09-20
  • DRep. Donald Sternoff BeyerOther$1,001 - $15,0002021-07-21

STOCK Act disclosures are filed up to 45 days after the trade. Amount is a disclosed range, not an exact figure.

Frequently asked questions

How many SEC Form 4 insider filings does NTLA have?

Intellia Therapeutics, Inc. (NTLA) has 29 SEC Form 4 filings (36 transaction rows) in the rolling 365-day window, disclosed by 8 distinct insiders. Most recent filing: Aug 24, 2026.

When was the most recent SEC Form 4 filing for NTLA?

The most recent Form 4 filing for NTLA on Tracefour is dated Aug 24, 2026.

Who is the most active insider at NTLA?

The most active SEC Form 4 filer at NTLA in the rolling window is President and CEO LEONARD JOHN M, with 4 filings.

What is the net insider flow at NTLA over the last 6 months?

Over the trailing 180 days, insiders at NTLA have net sold $532K based on SEC Form 4 disclosures.

What is the total insider buy and sell value at NTLA in the current window?

Inside the rolling window, insiders at NTLA bought $1.4M and sold $2.2M based on SEC Form 4 filings.

Can I get alerts for NTLA insider trading?

Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Intellia Therapeutics, Inc. (NTLA). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.

Related companies

Intellia Therapeutics, Inc. is in the Healthcare sector.